About this trial
This study aimed at helping researchers understand how a medication called haloperidol can affect insulin action in the brain. Insulin is a hormone in the body that controls sugar levels in part by lowering the amount of glucose produced by the liver. After eating a meal, insulin levels go up in both the blood and the brain. Insulin in the brain has also been shown to affect the way the brain works and processes information (also known as "cognition"). Haloperidol, is an antipsychotic medication used to treat a variety of disorders such as schizophrenia spectrum disorders, bipolar disorder, and major depressive disorder, but long-term use can have metabolic side effects, like weight gain, type 2 diabetes, and cardiovascular disease. The purpose of this study is to investigate how antipsychotic medications, such as haloperidol, which carries the risk of metabolic changes, might interrupt the effect of insulin action in the brain. This will help researchers learn how to potentially reduce metabolic risk for people who take these kinds of medications in the future.
Eligibility criteria
Qualifiers
Must be deemed to have the capacity to provide informed consent
Must sign and date the informed consent form
Stated willingness to comply with all study procedures;
Age: 18-35
Disqualifiers
History of psychiatric illness, including any substance use (screened using the Mini International Neuropsychiatric Interview (MINI))
Pre-diabetes or diabetes (fasting glucose ≥6.0 mmol/L, HbA1c>6% or use of anti-diabetic drug),
Evidence of impaired insulin sensitivity, assessed using the Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) ≥2.5
Family history of diabetes in a first degree relative (parent or sibling)
Trial design
Treatments tested in this trial
- Haloperidol
- Placebo
- Insulin Lispro
- Saline
Treatment groups
Sponsors and collaborators
Centre for Addiction and Mental Health
Lead sponsor
The Physicians' Services Incorporated Foundation
Collaborator